QURE UPDATE-! uniQure expects cash to fund operations into 1H24 07:14 QURE As of June 30, 2021, the Company's cash position was $677.3 million. The Company expects cash and cash equivalents will be sufficient to fund operations into the first half of 2024, excluding any of the $1.6 billion in future milestones or royalties on net sales the Company may receive under the CSL Behring Agreement. The receipt of approximately $300 million in milestone payments relates to regulatory submissions, first commercial sales and certain development milestones would be expected to extend the cash runway by approximately 18 months. Show Related Items >> ->uniQure expects to complete Corlieve acquisition in 3Q21 07:13 QURE In June, uniQure expects initial data for AMT-130 by year-end 07:12 QURE patients in its ongoing Phase I/II study of AMT-130 in Huntington's disease. The U.S. study is a multi-center, double-blinded, randomized and controlled trial to assess the safety and efficacy of AMT-130. The Data Safety Monitoring Board recommended proceeding with patient enrollment in the second dose cohort after reviewing nine-month safety data from the first two enrolled patients, six-month safety data from the next two enrolled patients, and the 30-day safety data from the remaining six patients. In June 2021, the Company announced the first two patient procedures were completed in the second dose cohort of Phase I/II clinical trial. Enrollment of the next two patient procedures will take place after a planned DSMB meeting expected to be held later in the third quarter of 2021. Initial data from the first four enrolled patients in this first-in-human AAV-gene therapy trial are anticipated by year-end 2021. The Company also remains on track to initiate an open label, Phase Ib/II clinical study of AMT-130 in Europe with enrollment beginning in the second half of 2021.
.... THE NEWS JUST KEEPS COMING! uniQure expects to sumbit BLA for AMT-061 in 1Q22 07:12 QURE In June 2021, the Company announced initial 52-week post-administration Factor IX data and annualized bleeding rates in the HOPE-B pivotal trial of etranacogene dezaparvovec in severe to moderately severe hemophilia B patients. Sustained increase in FIX levels was observed with a mean FIX activity of 41.5% of normal compared to 39.0% at 26-weeks post administration. During the 52-week period after dosing, patients reported an 80% reduction in total bleeding events requiring treatment, an 85% reduction in spontaneous bleeding events requiring treatment, and a 96% reduction in annualized usage of FIX replacement therapy. The Company expects all patients in the HOPE-B clinical trial to complete their 78-week follow-up visits by the end of the third quarter of 2021, and expects the BLA will be submitted in the first quarter of 2022. The Company announced the closing of the transaction with CSL Behring for its hemophilia B gene therapy following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on May 5, 2021. In accordance with the agreement, the upfront payment of $450 million was paid to uniQure on May 7, 2021. Oh Baby!
Folks I cannot believe what I am reading! - I need everybody in this stock the way Van is. uniQure reports Q2 EPS $8.51, consensus $2.96 -07:11 QURE Reports Q2 revenue $463.9M, consensus $190.02M. "We had a highly productive second quarter of this year marked by several notable achievements, including the closing on our global commercial licensing agreement with CSL Behring in hemophilia B and the recent presentation of 52-week data on all patients in our HOPE-B pivotal study showing durable and sustained increases in Factor IX levels within the non-hemophiliac range1, as well as significant reductions in both bleeding events and usage of replacement therapy after a one-time administration of etranacogene dezaparvovec," stated Matt Kapusta, chief executive officer at uniQure. "Additionally, we continued to make strong progress in our U.S. Phase I/II study of AMT-130 in Huntington's disease, including the completion of patient enrollment in the first dose cohort and the initiation of dosing in the second cohort. We also recently hosted a Research and Development Day where we disclosed four new promising research programs that complemented our expanding focus in neurological disease and larger patient populations, including the acquisition of Corlieve Therapeutics and its gene therapy program targeting temporal lobe epilepsy that builds on our expanding focus in serious neurological diseases," he added. "These investments deliver on our commitment to leverage our strong cash position to invest in new research programs and enabling technologies with the potential to drive significant value. In the second half of 2021, we expect to continue our progress across all programs, including availability of 78-week data from the HOPE-B study, initiating patient enrollment for our open-label European study of AMT-130 in Huntington's disease, and announcing initial data on the first four randomized Huntington's disease patients in the ongoing U.S. Phase I/II study."
WARNING- 2ND COMPANY TO SAY THIS--- RPM sees 1H22 performance 'significantly impacted by inflation' 06:47 RPM "As mentioned last quarter, a number of macroeconomic factors are creating inflationary and supply pressures on some of our product categories. Due to the lag impact resulting from our FIFO accounting methodology, we expect that our fiscal 2022 first-half performance will be significantly impacted by inflation throughout our P&L
Greenbrier upgraded to Positive from Neutral at Susquehanna 05:18 GBX Susquehanna analyst Bascome Majors upgraded Greenbrier to Positive from Neutral with a $56 price target. I don't like getting too hyped up but this next upgrade contains some buzz words that has be excited-- Point Biopharma initiated with an Overweight at Piper Sandler 05:08 PNT Piper Sandler analyst Edward Tenthoff initiated coverage of Point Biopharma with an Overweight rating and $17 price target. The company is revolutionizing precision radiotherapies and has built a state-of-the-art radiopharmaceuticals manufacturing facility, Tenthoff tells investors in a research note. While early, he believes PNT2003 has the potential to transform radiotherapy. PNT-$8.88
I mean I have a rule I follow every sk 2 weeks before buying but this was $17! POINT Biopharma Global Inc. (PNT) 9.04+0.04 (+0.44%) As of 9:31AM EDT. Market open.
ELYS closed a US purchase that was supposed to give it some kind of footprint here the stk went to $4.40 last week I believe and crashed back. No thrust today on upgrade... It just trades poorly. Entain Plc (GMVHF) Has Been The way To Go! BIG BOTTOMS ARE BEAUTIFUL! (SORT OF) PEOPLE GOT FAT DURING COVID! HEAVY GALS NEED GOOD CLOTHES! sizes 10-30!!!<--- THIS STK WAS $28 IN JULY!!!!<---- Torrid Holdings Inc. (CURV) 23.25+0.77 (+3.43%)